Composition and methods for treating articulating joint disorders with nucleoside reverse transcriptase inhibitors
Described herein is are compositions and methods for treating an articulating joint disorders, comprising systemically administering to a subject a nucleoside reverse transcriptase inhibitor (NRTI).
1. A method for inhibiting the progression of an articulating joint disorder by inhibiting LINE-1 expression in a subject, comprising systemically administering emtricitabine to said subject, wherein said subject does not comprise a human immunodeficiency virus (HIV) infection.
2. The method of claim 1 , wherein said subject is diagnosed as comprising osteoarthritis.
3. The method of claim 1 , wherein said joint disorder comprises osteoarthritis (OA).
4. A method for inhibiting the progression of an aging-associated joint disorder by inhibiting LINE-1 expression in a subject, comprising systemically administering emtricitabine to said subject, wherein said subject does not comprise a human immunodeficiency virus (HIV) infection.
5. The method of claim 4 , wherein the subject is at least 50 years old.
6. The method of claim 4 , wherein the joint disorder comprises osteoarthritis.
7. The method of claim 4 , wherein the subject is a human.
8. The method of claim 4 , wherein the emtricitabine inhibits the expression of osteoarthritis markers.
9. The method of claim 8 , wherein the osteoarthritis markers comprise collagen type X alpha 1 chain (COL10A1), A Disintegrin and Metalloproteinase with Thrombospondin Motifs 5 (ADAMTS5), matrix metallopeptidase 13 (MMP13), senescence-associated secretory phenotype interleukin-6 (SASP IL-6), Indian hedgehog (Ihh) or interferon type 1 (IFN).
10. The method of claim 4 , wherein the emtricitabine promotes the expression of anabolic markers.
11. The method of claim 10 , wherein the anabolic markers comprise aggrecan (ACAN) and Collagen, type II, alpha 1 (COL2A1).
12. A method for inhibiting the progression of a post-traumatic osteoarthritis (PTOA) injury by inhibiting LINE-1 expression in a subject, comprising systemically administering emtricitabine to said subject, wherein said subject does not comprises a human immunodeficiency virus (HIV) infection.
13. The method of claim 12 , wherein said PTOA results from a high-speed impact trauma to the articular surface, intraarticular fractures, or joint-destabilizing soft-tissue tears.
14. The method of claim 12 , wherein the PTOA injury is in a joint.